Park JS, Park MC, Song JJ, Park YB, Lee SK, Lee SW. Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon. Arthritis Res Ther. 2015 Mar 22. 17(1):77. [QxMD MEDLINE Link]. [Full Text].
Sakkas LI. New developments in the pathogenesis of systemic sclerosis. Autoimmunity. 2005 Mar. 38(2):113-6. [QxMD MEDLINE Link].
Troldborg A, Nielsen BD, Kolstad HA, Olesen AB, Søndergaard KH. [Silica exposure and the risk of systemic sclerosis.]. Ugeskr Laeger. 2013 Feb 18. 175(8):501-503. [QxMD MEDLINE Link].
Alaya Z, Kalboussi H, Osman W, Naouar N, Zeglaoui H, Bouajina E. [Silica-associated systemic sclerosis occurring after an occupational exposure to arc welding]. Pan Afr Med J. 2016. 25:70. [QxMD MEDLINE Link].
Kawakami T, Tsutsumi Y, Soma Y. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer. Arch Dermatol. 2009 Jan. 145(1):97-8. [QxMD MEDLINE Link].
Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019. 11:257-273. [QxMD MEDLINE Link].
Nguyen C, Berezne A, Baubet T, et al. Association of Gender with Clinical Expression, Quality of Life, Disability, and Depression and Anxiety in Patients with Systemic Sclerosis. PLoS One. 2011 Mar 9. 6(3):e17551. [QxMD MEDLINE Link]. [Full Text].
Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009 Feb. 60(2):569-77. [QxMD MEDLINE Link].
Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV, et al. Early- versus Late-Onset Systemic Sclerosis: Differences in Clinical Presentation and Outcome in 1037 Patients. Medicine (Baltimore). 2014 Mar. 93(2):73-81. [QxMD MEDLINE Link].
Hissaria P, Roberts-Thomson PJ, Lester S, Ahern MJ, Smith MD, Walker JG. Cigarette smoking in patients with systemic sclerosis - reduces overall survival. Arthritis Rheum. 2011 Mar 24. [QxMD MEDLINE Link].
Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega JC, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019 Apr 3. 21 (1):86. [QxMD MEDLINE Link].
Jung S, Martin T, Schmittbuhl M, Huck O. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management. Oral Dis. 2016 May 19. [QxMD MEDLINE Link].
Mozzetta A, Antinone V, Alfani S, et al. Mental health in patients with systemic sclerosis: a controlled investigation. J Eur Acad Dermatol Venereol. 2008 Mar. 22(3):336-40. [QxMD MEDLINE Link].
Kwakkenbos L, van Lankveld WG, Vonk MC, Becker ES, van den Hoogen FH, van den Ende CH. Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. J Psychosom Res. 2012 Mar. 72(3):199-204. [QxMD MEDLINE Link].
Peytrignet S, Denton CP, Lunt M, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology (Oxford). 2018 Feb 1. 57 (2):370-381. [QxMD MEDLINE Link].
Hudson M, Steele R, Taillefer S, Baron M; Canadian Scleroderma Research. Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum. 2008 Jan 31. 59(2):270-278. [QxMD MEDLINE Link].
Ungprasert P, Srivali N, Kittanamongkolchai W. Systemic sclerosis and risk of venous thromboembolism: A systematic review and meta-analysis. Mod Rheumatol. 2015 Apr 7. 1-17. [QxMD MEDLINE Link].
Malcarne VL, Hansdottir I, McKinney A. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol. 2007 Feb. 34(2):359-67. [QxMD MEDLINE Link].
Horimoto AMC, de Souza AS, Rodrigues SH, Kayser C. Risk of digital ulcers occurrence in systemic sclerosis: a cross-sectional study. Adv Rheumatol. 2019 Mar 28. 59 (1):14. [QxMD MEDLINE Link].
Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol. 2020 Feb 25. [QxMD MEDLINE Link].
Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody--a specific marker of systemic sclerosis. Br J Dermatol. 1986 Oct. 115(4):393-401. [QxMD MEDLINE Link].
Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med. 1997 Sep. 103(3):242-8. [QxMD MEDLINE Link].
Dogan S, Akdogan A, Atakan N. Nailfold capillaroscopy in systemic sclerosis: Is there any difference between videocapillaroscopy and dermatoscopy?. Skin Res Technol. 2013 Mar 25. [QxMD MEDLINE Link].
Avouac J, Lepri G, Smith V, Toniolo E, Hurabielle C, Vallet A, et al. Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. Semin Arthritis Rheum. 2017 Feb 10. [QxMD MEDLINE Link].
Lambova SN, Müller-Ladner U. Mosaic capillaroscopic findings in systemic sclerosis. Wien Med Wochenschr. 2018 Feb 1. [QxMD MEDLINE Link].
Aozasa N, Asano Y, Ashida R, et al. Systemic sclerosis with an unusual rapid development of huge calcinosis (tumoral calcinosis). J Dermatol. 2011 Mar 2. [QxMD MEDLINE Link].
Modak R, Viswanath V. Calcinosis cutis universalis in systemic sclerosis. Indian J Dermatol Venereol Leprol. 2018 Feb 14. [QxMD MEDLINE Link].
Wielosz E, Borys O, Zychowska I, Majdan M. Gastrointestinal involvement in patients with systemic sclerosis. Pol Arch Med Wewn. 2010 Apr. 120(4):132-6. [QxMD MEDLINE Link].
Schieir O, Thombs BD, Hudson M, Boivin JF, Steele R, Bernatsky S, et al. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. Arthritis Care Res (Hoboken). 2010 Mar. 62(3):409-17. [QxMD MEDLINE Link].
Scope A, Sadetzki S, Sidi Y, et al. Breast cancer and scleroderma. Skinmed. 2006 Jan-Feb. 5(1):18-24. [QxMD MEDLINE Link].
Khoo JJ, Pratt EJ. Phaeochromocytoma mimicking scleroderma. Int J Endocrinol. 2011. 2011:917453. [QxMD MEDLINE Link]. [Full Text].
Itoh M, Yanaba K, Kobayashi T, Nakagawa H. Taxane-induced scleroderma. Br J Dermatol. 2007 Feb. 156(2):363-7. [QxMD MEDLINE Link].
Chen JK, Chung L, Fiorentino DF. Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series. J Am Acad Dermatol. 2016 Jun. 74 (6):1272-4. [QxMD MEDLINE Link].
Muangchan C, Harding S, Khimdas S, Bonner A, Baron M, Pope J. C - reactive protein (CRP) is associated with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG). Arthritis Care Res (Hoboken). 2012 May 3. [QxMD MEDLINE Link].
Waszczykowska E, Kukulski K, Sysa-Jedrzejowska A, Dziankowska-Bartkowiak B, Gierach D, Omulecki A. Evaluation of esophageal passage in selected connective tissue diseases. J Med. 1997. 28(3-4):163-74. [QxMD MEDLINE Link].
Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol. 2015 Feb 15. 15(1):24. [QxMD MEDLINE Link]. [Full Text].
de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008 Jan. 67(1):31-6. [QxMD MEDLINE Link].
Foocharoen C, Pussadhamma B, Mahakkanukrauh A, Suwannaroj S, Nanagara R. Asymptomatic cardiac involvement in Thai systemic sclerosis: prevalence and clinical correlations with non-cardiac manifestations (preliminary report). Rheumatology (Oxford). 2015 Apr 10. [QxMD MEDLINE Link].
Cianci R, Gigante A, Gasperini ML, Barbano B, Galea N, Rosato E. Late Gadolinium Enhancement in Cardiac Magnetic Resonance Imaging Is Associated with High Renal Resistive Index in Patients with Systemic Sclerosis. Kidney Blood Press Res. 2020. 45 (2):350-356. [QxMD MEDLINE Link].
Kepez A, Akdogan A, Sade LE, et al. Detection of Subclinical Cardiac Involvement in Systemic Sclerosis by Echocardiographic Strain Imaging. Echocardiography. 2008 Feb. 25(2):191-197. [QxMD MEDLINE Link].
Waszczykowska A, Gos R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P. Assessment of skin microcirculation by laser Doppler flowmetry in systemic sclerosis patients. Postepy Dermatol Alergol. 2014 Feb. 31(1):6-11. [QxMD MEDLINE Link]. [Full Text].
Dźwigała M, Sobolewski P, Maślińska M, Yurtsever I, Szymańska E, Walecka I. High-resolution ultrasound imaging of skin involvement in systemic sclerosis: a systematic review. Rheumatol Int. 2021 Feb. 41 (2):285-295. [QxMD MEDLINE Link].
De Santis M, Bosello SL, Capoluongo E, Inzitari R, Peluso G, Lulli P, et al. A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Ann Rheum Dis. 2012 Mar 27. [QxMD MEDLINE Link].
Blaszczyk M, Jarzabek-Chorzelska M, Jablonska S, et al. Autoantibodies to nucleolar antigens in systemic scleroderma: clinical correlations. Br J Dermatol. 1990 Oct. 123(4):421-30. [QxMD MEDLINE Link].
Bruns M, Herrmann K, Haustein UF. Immunologic parameters in systemic sclerosis. Int J Dermatol. 1994 Jan. 33(1):25-32. [QxMD MEDLINE Link].
Van Praet JT, Smith V, Haspeslagh M, Degryse N, Elewaut D, De Keyser F. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther. 2011 Feb 28. 13(1):R35. [QxMD MEDLINE Link].
Ohtsuka T. Relation between elevated high-sensitivity C-reactive protein and anti-mitochondria antibody in patients with systemic sclerosis. J Dermatol. 2008 Feb. 35(2):70-5. [QxMD MEDLINE Link].
Mostmans Y, Richert B, Badot V, Nagant C, Smith V, Michel O. The importance of skin manifestations, serology and nailfold (video)capillaroscopy in morphea and systemic sclerosis: current understanding and new insights. J Eur Acad Dermatol Venereol. 2021 Mar. 35 (3):597-606. [QxMD MEDLINE Link].
Van Praet JT, Van Steendam K, Smith V, et al. Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach. Rheumatology (Oxford). 2011 Feb 17. [QxMD MEDLINE Link].
García de la Peña Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Román Ivorra JA, et al. Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. Rheumatol Int. 2015 Apr 1. [QxMD MEDLINE Link].
Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998 Apr. 41(4):670-7. [QxMD MEDLINE Link].
Krasagakis K, Dippel E, Ramaker J, Owsianowski M, Orfanos CE. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology. 1998. 196(3):309-15. [QxMD MEDLINE Link].
Seyger MM, van den Hoogen FH, van Vlijmen-Willems IM, van de Kerkhof PC, de Jong EM. Localized and systemic scleroderma show different histological responses to methotrexate therapy. J Pathol. 2001 Apr. 193(4):511-6. [QxMD MEDLINE Link].
Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset. J Rheumatol. 2012 Apr 1. [QxMD MEDLINE Link].
Hider SL, Woodhead M, Taylor PM, Bruce IN. Lung fibrosis in systemic sclerosis treated with a combination of ciclosporin and azathioprine. Clin Exp Rheumatol. 2006 Mar-Apr. 24(2):215. [QxMD MEDLINE Link].
Valentini G, Paone C, La Montagna G, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol. 2006 Jan-Feb. 35(1):35-8. [QxMD MEDLINE Link].
Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol. 1998 Jul. 25(7):1325-9. [QxMD MEDLINE Link].
Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis. 2006 Aug. 65(8):1118-20. [QxMD MEDLINE Link].
Blagojevic J, Matucci-Cerinic M. Are statins useful for treating vascular involvement in systemic sclerosis?. Nat Clin Pract Rheumatol. 2009 Feb. 5(2):70-1. [QxMD MEDLINE Link].
Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma--where histological and clinical scores meet. Rheumatology (Oxford). 2007 May. 46(5):833-41. [QxMD MEDLINE Link].
Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2015 Apr 9. [QxMD MEDLINE Link].
Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum. 2009 Jan 29. 60(2):584-591. [QxMD MEDLINE Link].
Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 2008 Aug. 58(8):2528-37. [QxMD MEDLINE Link].
Halachmi S, Gabari O, Cohen S, Koren R, Amitai DB, Lapidoth M. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. Lasers Med Sci. 2013 Mar 14. [QxMD MEDLINE Link].
Dinsdale G, Murray A, Moore T, Ferguson J, Wilkinson J, Richards H, et al. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology (Oxford). 2014 Mar 28. [QxMD MEDLINE Link].
Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, et al. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018 Jan 1. 57 (1):152-157. [QxMD MEDLINE Link].
Varrica C, Dias HS, Reis C, Carvalheiro M, Simões S. Targeted delivery in scleroderma fibrosis. Autoimmun Rev. 2021 Feb. 20 (2):102730. [QxMD MEDLINE Link].
Riera R, Andrade LE, Souza AW, Kayser C, Yanagita ET, Trevisani VF. Lidocaine for systemic sclerosis: a double-blind randomized clinical trial. Orphanet J Rare Dis. 2011 Feb 7. 6:5. [QxMD MEDLINE Link]. [Full Text].